Synergy Disc
Synergy Spine Solutions, Inc. · Decision date Feb 26, 2026
What did the FDA approve?
FDA records P250028 as an original PMA application. The recorded decision is approval, dated Feb 26, 2026.
FDA approval order statement
The Synergy Disc is indicated in skeletally mature patients for reconstruction of the disc at one level from C3-C7 following single-level discectomy for intractable radiculopathy (arm pain and/or a neurological deficit) with or without neck pain, or myelopathy due to a single-level abnormality localized to the level of the disc space and at least one of the following conditions confirmed by radiographic imaging (CT, MRI, X-rays): herniated nucleus pulposus, spondylosis (defined by the presence of osteophytes), and/or visible loss of disc height compared to adjacent levels. The Synergy Disc is implanted using an anterior approach. Patients should have failed at least 6 weeks of conservative treatment or demonstrated progressive signs or symptoms despite nonoperative treatment prior to implantation of the Synergy Disc.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Orthopedic
- Decision date
- Feb 26, 2026
Regulatory record facts
- Identifier
- P250028
- Regulatory pathway
- Premarket approval application
- Applicant
- Synergy Spine Solutions, Inc.
- Product code
- MJO
- Decision code
- APPR
- Decision date
- Feb 26, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Prosthesis, intervertebral disc.
- Applicant
- Synergy Spine Solutions, Inc.
- Product code
- MJO
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P250028 received
Application receipt date recorded by FDA.
P250028 · FDA decision
APPR
P250028/S003 · Related supplement
Synergy Disc
Timeline entries are records held by MedtechLedger for P250028. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P250028
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Synergy DiscP250028/S003 | Synergy Spine Solutions, Inc. | PMA supplement | Sep 17, 2026 | FDA |
Explore the linked device profile
Other records with product code MJO
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
BAGUERAC Cervical Disc ProsthesisP250042/S002 | Spineart USA, Inc. | PMA supplement | Sep 22, 2026 | FDA |
| Highridge Medical, LLC | PMA supplement | Sep 16, 2026 | FDA | |
| Highridge Medical, LLC | PMA supplement | Sep 16, 2026 | FDA | |
prodisc C NovaP070001/S031 | Centinel Spine, LLC | PMA supplement | Sep 9, 2026 | FDA |
| Spineart USA, Inc. | PMA approval | Aug 10, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Synergy Spine Solutions, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 357 S. Mccaslin Blvd., Suite 120, Louisville, CO, 80027
Sources and methodology
- Original FDA record: P250028
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



